Latest / DDReg Knowledge Capsule / Sri Lanka’s 2026 Medical Device Regulatory Registration

Transcript

Sri Lanka’s 2026 Medical Device Regulatory Registration · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to ddragnowledge capsule.
• 0:01
  Speaker 2: Glad to be here.
• 0:02
  Speaker 1: So imagine this. You spend eighteen months, right and millions
• 0:07
  Speaker 1: of dollars proving your newly engineered diagnostic scanner is perfectly
• 0:12
  Speaker 1: safe for the European market, which is.
• 0:14
  Speaker 2: An exhaustive process on its own.
• 0:16
  Speaker 1: Right, You finally get the green light. Then you decide, hey,
• 0:19
  Speaker 1: let's expand our sales into South Asia.
• 0:21
  Speaker 2: Makes sense.
• 0:22
  Speaker 1: But instead of leveraging all that rigorous scientific proof youg
• 0:25
  Speaker 1: just compiled, the local authorities tell you to well start
• 0:28
  Speaker 1: completely from scratch.
• 0:29
  Speaker 2: Yeah, that's the classic nightmare scenario exactly.
• 0:33
  Speaker 1: It's a scenario that has historically frustrated global manufacturers to
• 0:38
  Speaker 1: no end. Navigating international expansion often meant dealing with duplicated efforts,
• 0:43
  Speaker 1: opaque requirements, and wildly unpredictable timelines.
• 0:46
  Speaker 2: It really is a massive friction point. I mean, regulatory
• 0:49
  Speaker 2: affairs professionals, they crave visibility, they want standardized systems, absolutely,
• 0:53
  Speaker 2: But for a long time, entering emerging markets felt like
• 0:56
  Speaker 2: charting unknown territory. You had independent health meat industries demanding localized,
• 1:01
  Speaker 2: redundant clinical reviews.
• 1:03
  Speaker 1: And they didn't always have the resources for that, right.
• 1:05
  Speaker 2: No, exactly, they didn't necessarily have the deep institutional bandwidth
• 1:10
  Speaker 2: to process them efficiently. So the result was this massive.
• 1:13
  Speaker 1: Bottleneck which keeps life saving technologies away from the patients
• 1:17
  Speaker 1: who actually need them.
• 1:18
  Speaker 2: Right while simultaneously stalling business growth for the manufacturers. It
• 1:21
  Speaker 2: was a lose lose, but.
• 1:22
  Speaker 1: You know, the landscape is shifting dramatically today. We are
• 1:25
  Speaker 1: looking at a specific case study that changes the blueprint.
• 1:28
  Speaker 1: We're talking about Sri Lanka's twenty twenty six transformation of
• 1:32
  Speaker 1: its medical device regulatory framework.
• 1:34
  Speaker 2: It's a huge overhaul.
• 1:36
  Speaker 1: It really is so for you listening, whether you are
• 1:39
  Speaker 1: a regulatory affairs professional mapping out an expansion strategy into
• 1:42
  Speaker 1: South Asia, or just a curious learner fascinated by how
• 1:46
  Speaker 1: global health bureaucracies are finally harmonizing to become more efficient.
• 1:51
  Speaker 1: This deep dive is your shortcut to understanding international regulatory reliance.
• 1:56
  Speaker 2: Yeah, we are going to unpack how a historically informal
• 1:59
  Speaker 2: kind of fragment market has been completely overhauled into a
• 2:03
  Speaker 2: highly structured, streamlined opportunity.
• 2:05
  Speaker 1: Let's start with the anchor for this entire shift, which
• 2:08
  Speaker 1: is the NMRA.
• 2:10
  Speaker 2: Right, the National Medicine's Regulatory Authority Now The agency itself
• 2:15
  Speaker 2: was established back by the twenty fifteen Act, and in
• 2:18
  Speaker 2: its early days, the approach to medical device import and
• 2:21
  Speaker 2: market authorization in Sri Lanka was relatively informal.
• 2:25
  Speaker 1: It relied on a patchwork of temporary approvals, didn't it? Yeah?
• 2:28
  Speaker 2: Mostly. But what makes twenty twenty six the real inflection
• 2:32
  Speaker 2: point is that the NMRA has now fully operationalized mandatory
• 2:38
  Speaker 2: registration and it's under a very rigid, modern framework.
• 2:42
  Speaker 1: And this matters because Sri Lanka has a growing health infrastructure,
• 2:45
  Speaker 1: not to mention a highly resilient private healthcare sector.
• 2:48
  Speaker 2: Exactly, it's a market you want to be in.
• 2:49
  Speaker 1: So to participate in that growing market, global manufacturers can
• 2:53
  Speaker 1: no longer rely on those old informal pathways. They have
• 2:56
  Speaker 1: to pass through a highly modernized set of toll gates.
• 2:59
  Speaker 2: Yep, the free for all is over right.
• 3:01
  Speaker 1: So before we explore how a company might fastrack their
• 3:03
  Speaker 1: way into Sri Lanka, you first need to understand those
• 3:06
  Speaker 1: fundamental gaits. Basically, the NMRA has instituted a risk based
• 3:10
  Speaker 1: categorization system, which.
• 3:12
  Speaker 2: I should note is the global standard for regulating medical technology.
• 3:16
  Speaker 1: Right, rather than treating say, a wooden tongue depressor and
• 3:20
  Speaker 1: a robotic surgical arm as the same kind.
• 3:22
  Speaker 2: Of import Exactly, they evaluate the specific danger a device poses.
• 3:27
  Speaker 2: They are broadly aligning with the principles set out by
• 3:30
  Speaker 2: the Global Harmonization Task Force known as the GHTF, as
• 3:34
  Speaker 2: well as European Union guidelines.
• 3:36
  Speaker 1: So they're looking at things like the intended purpose of
• 3:39
  Speaker 1: the device, the duration of continuous use, the.
• 3:42
  Speaker 2: Degree of invasiveness too, and of course the overall potential
• 3:46
  Speaker 2: risk to the patient and the user.
• 3:48
  Speaker 1: And then they slot every general medical device into Class one,
• 3:51
  Speaker 1: Class two A, Class two B, or Class three.
• 3:53
  Speaker 2: That progressive ladder of scrutiny ensures that the regulatory burden
• 3:57
  Speaker 2: actually matches the clinical risk.
• 4:00
  Speaker 1: One covers the low risk items.
• 4:01
  Speaker 2: Right your non invasive everyday.
• 4:03
  Speaker 1: Essentials, yeah, examination gloves, basic corrective glasses, or standard hospital beds.
• 4:08
  Speaker 2: Basically devices where a failure or malfunction is highly unlikely
• 4:12
  Speaker 2: to cause serious injury or you know, pose any systemic
• 4:16
  Speaker 2: risk to the patient.
• 4:17
  Speaker 1: Class one devices, your bandages and basic tools essentially get
• 4:21
  Speaker 1: the TSA PreCheck treatment.
• 4:23
  Speaker 2: That's a great analogy.
• 4:24
  Speaker 1: They face the lowest barrier to entry. It is almost
• 4:26
  Speaker 1: as if the device is walking up to the security
• 4:28
  Speaker 1: line saying, I am a low risk Class one device,
• 4:32
  Speaker 1: let me through, right.
• 4:33
  Speaker 2: They require the least amount of technical friction and documentation
• 4:37
  Speaker 2: to get through the gate, but that changes quickly as
• 4:40
  Speaker 2: the clinical stakes increase. Naturally, from there, the scrutiny scales
• 4:44
  Speaker 2: up to Class two A, which is the low medium
• 4:47
  Speaker 2: risk category.
• 4:48
  Speaker 1: And what fits in there?
• 4:49
  Speaker 2: This classification generally captures devices that might have limited patient contact,
• 4:53
  Speaker 2: or maybe they channel fluids into the body or are
• 4:56
  Speaker 2: used in a slightly more complex diagnostic context. Think of
• 5:00
  Speaker 2: hypodermic needles, suction equipment, or standard electronic blood pressure monitors.
• 5:05
  Speaker 1: Okay, so we move from the external bandage to a
• 5:08
  Speaker 1: needle penetrating the skin, the potential for harm like an
• 5:11
  Speaker 1: infection is.
• 5:12
  Speaker 2: Higher, exactly. And then we hit the heavy machinery. Class
• 5:15
  Speaker 2: two B is medium high risk.
• 5:17
  Speaker 1: So things with sustained contact.
• 5:19
  Speaker 2: Yeah, here we are looking at devices that have significant,
• 5:22
  Speaker 2: often sustained patient contact or active devices utilized for critical monitoring.
• 5:29
  Speaker 2: A malfunctioning infusion pump delivering incorrect medication dosages, or faulty
• 5:35
  Speaker 2: diagnostic imaging equipment that could lead to a misdiagnosis falls
• 5:39
  Speaker 2: right here.
• 5:39
  Speaker 1: Oh wow, Yeah, that's serious.
• 5:41
  Speaker 2: You'll also find some implantable devices in this tier.
• 5:44
  Speaker 1: Finally, you reach the APEX, which is Class three, the
• 5:47
  Speaker 1: highest risk category. I imagine this involves devices air acting
• 5:51
  Speaker 1: directly with the most critical human organs.
• 5:53
  Speaker 2: It does that covers devices in direct contact with the
• 5:57
  Speaker 2: central cardiovascular system or the central nervous system. I mean
• 6:00
  Speaker 2: a failure here is typically immediately life threatening.
• 6:03
  Speaker 1: Like neurostimulators or implantable pacemakers exactly. But Class three devices
• 6:08
  Speaker 1: such as cardiac stents are getting pulled aside for the
• 6:11
  Speaker 1: intense background check. Oh, there is no quick PreCheck for
• 6:15
  Speaker 1: a device designed to hold open an artery.
• 6:17
  Speaker 2: Nor should there be. And as a quick aside, it
• 6:20
  Speaker 2: is worth noting that in vitro diagnostics, the read agents
• 6:25
  Speaker 2: and tools used to test blood or tissue samples outside
• 6:28
  Speaker 2: the body, those are classified entirely separately under their own
• 6:32
  Speaker 2: dedicated four tier framework.
• 6:34
  Speaker 1: Okay, so let me pause and play the role of
• 6:36
  Speaker 1: a manufacturer sitting in say Berlin or Paris.
• 6:39
  Speaker 2: Okay, go for it.
• 6:40
  Speaker 1: If my company has already gone through the incredibly rigorous
• 6:44
  Speaker 1: multi year process to classify our device under the European
• 6:48
  Speaker 1: Union's Medical Device regulation or in vitro diagnostic regulation, usually
• 6:53
  Speaker 1: referred to under their MDR or IVDR frameworks. Can I
• 6:57
  Speaker 1: just bypass the Sri Lankan classification.
• 6:59
  Speaker 2: Step port it over?
• 7:00
  Speaker 1: Yeah? Does my EU paperwork automatically dictate my Sri Lankan
• 7:04
  Speaker 1: classification or does the NMRA have the final say?
• 7:08
  Speaker 2: That's a common question, but no, the NMRA always has
• 7:11
  Speaker 2: the final. Say, a manufacturer cannot unilaterally declare their final
• 7:14
  Speaker 2: class in Sri Lanka based purely on foreign paperwork. That
• 7:17
  Speaker 2: makes sense, however, because the NMRA classification rules follow the
• 7:21
  Speaker 2: same foundational GHTF logic as Europe, the process will feel
• 7:25
  Speaker 2: very familiar. You cannot simply copy and paste your European designation,
• 7:30
  Speaker 2: but you are speaking the same underlying regulatory language, so
• 7:34
  Speaker 2: they just verify it exactly. The NMRA simply reviews your submission,
• 7:39
  Speaker 2: confirms your logic, and determines the final class at the
• 7:43
  Speaker 2: time of the registration review.
• 7:44
  Speaker 1: Okay, so once a company understands its risk class, the
• 7:47
  Speaker 1: immediate priority becomes speed to market.
• 7:50
  Speaker 2: Always time is money, exactly.
• 7:52
  Speaker 1: Knowing that strict, intensive technical reviews exist for those higher
• 7:56
  Speaker 1: class devices, how does a manufacturer avoid waiting twelve to
• 8:00
  Speaker 1: eighteen months for approval in Sri Lanka?
• 8:02
  Speaker 2: Well, this leads us directly to the most strategically significant
• 8:05
  Speaker 2: feature of this twenty twenty six framework.
• 8:07
  Speaker 1: The Global Recognition Pathway.
• 8:09
  Speaker 2: Yes, this is where we see the concept of regulatory
• 8:11
  Speaker 2: reliance put into practice.
• 8:13
  Speaker 1: Regulatory reliance.
• 8:14
  Speaker 2: Yeah, it's a growing global trend where smaller regulatory bodies
• 8:18
  Speaker 2: leverage the evaluations performed by larger, better resource authorities to
• 8:22
  Speaker 2: inform their own decision making.
• 8:24
  Speaker 1: So the Global Recognition Pathway is basically a streamlined registration
• 8:29
  Speaker 1: mechanism tailored for devices that already hold a valid marketing
• 8:32
  Speaker 1: authorization from a designated reference country. You've got it, essentially,
• 8:37
  Speaker 1: if a device has passed the toughest scientific evaluations in
• 8:40
  Speaker 1: the world. Sri Lanka provides a fast track option, right.
• 8:44
  Speaker 2: And the list of recognized reference authorities is highly intentional.
• 8:48
  Speaker 2: It shows a deep alignment with the International Medical Device
• 8:51
  Speaker 2: Regulator's Forum or IMDRF, and that's.
• 8:55
  Speaker 1: A voluntary group of medical device regulators from around the
• 8:58
  Speaker 1: world who aim to accelerate in national harmonization.
• 9:01
  Speaker 2: Right exactly. So let's look at their lists.
• 9:03
  Speaker 1: Let's break down that list of reference authorities. When looking
• 9:05
  Speaker 1: at the us FDA, they recognize specifically their five ten
• 9:10
  Speaker 1: K clearances or pre market approvals.
• 9:12
  Speaker 2: Yes, and they also recognize the European Union's CE marking.
• 9:15
  Speaker 1: And looking to the east and south, they recognize Australia's
• 9:18
  Speaker 1: TGA and Japan's PMDA yep.
• 9:21
  Speaker 2: And rounding out the list you have the post brexit
• 9:24
  Speaker 2: UKCA marking from the United Kingdom and helped Canada's medical
• 9:28
  Speaker 2: device license.
• 9:29
  Speaker 1: So holding a current valid approval from one of those
• 9:32
  Speaker 1: agencies drastically reduces the timeline.
• 9:35
  Speaker 2: Oh significantly. Under a standard full review, complex devices easily
• 9:40
  Speaker 2: face a twelve to eighteen month wait, but through this
• 9:43
  Speaker 2: abridged pathway, it's much faster, much faster. But we need
• 9:46
  Speaker 2: to connect this to how the NMR structures technical files
• 9:52
  Speaker 2: which they categorize into dossier class's ABCND.
• 9:56
  Speaker 1: Okay, and those map to the risk classes exactly.
• 9:59
  Speaker 2: They directly mirror the numerical risk classes we discussed. Dossier
• 10:03
  Speaker 2: class as for Class one devices, Dossier B is for
• 10:05
  Speaker 2: Class two way and so on.
• 10:06
  Speaker 1: Right.
• 10:07
  Speaker 2: So, through the Global Recognition pathway, applicants are seeing total
• 10:10
  Speaker 2: timelines drop to approximately three to six months for dossier
• 10:14
  Speaker 2: Class B and C devices.
• 10:15
  Speaker 1: Wow, that's a huge drop.
• 10:17
  Speaker 2: Yeah, and even for dossier Class D submissions correlating to
• 10:20
  Speaker 2: the highest risk Class three devices, the timeline compresses down
• 10:23
  Speaker 2: to just four to eight months.
• 10:24
  Speaker 1: Wait, if the NMRA is essentially recognizing an FDA or
• 10:29
  Speaker 1: EU approval to skip the full technical review, what are
• 10:32
  Speaker 1: they actually reviewing? Are they just taking the manufacturer's word
• 10:35
  Speaker 1: for it.
• 10:35
  Speaker 2: I'm glad you brought that up, because it is a
• 10:37
  Speaker 2: critical distinction to make. Regulatory reliance is not blind rubber stamping. Okay,
• 10:42
  Speaker 2: The NMR possesses a highly skilled team of reviewers, but
• 10:47
  Speaker 2: they do not have the infinite budget or personnel bandwidth
• 10:51
  Speaker 2: of the FDA or the European Medicines Agency. Right few
• 10:54
  Speaker 2: do exactly, So, instead of spending thousands of hours duplicating
• 10:58
  Speaker 2: a complex scientific of valuation of clinical trial data that
• 11:02
  Speaker 2: the FDA has already validated, they delegate that specific scientific rigor.
• 11:06
  Speaker 1: And that frees them up to focus their resources entirely
• 11:09
  Speaker 1: on market specific safety.
• 11:11
  Speaker 2: Meaning they verify the foreign approval is legitimate and then
• 11:14
  Speaker 2: ensure the device will work safely in their specific local context.
• 11:18
  Speaker 2: Say they rigorously review the manufacturer's declaration of conformity, they
• 11:22
  Speaker 2: require a certificate of free sale from the reference country.
• 11:25
  Speaker 1: Ah okay, why is that certificate so crucial.
• 11:29
  Speaker 2: It proves to the NMR that the device isn't just
• 11:33
  Speaker 2: approved for export, meaning it isn't a substandard version built
• 11:37
  Speaker 2: only to be shipped overseas. It proves it is actually
• 11:40
  Speaker 2: legally marketed and used by citizens within that highly regulated
• 11:44
  Speaker 2: reference country. Furthermore, they review local adaptations, ensuring the packaging,
• 11:49
  Speaker 2: instructions and post market commitments are appropriate for the Sri
• 11:53
  Speaker 2: Lankan medical system.
• 11:54
  Speaker 1: That makes incredible strategic sense. They delegate the raw science
• 11:58
  Speaker 1: to the massive agencies can focus entirely on local implementation exactly.
• 12:04
  Speaker 1: But the global recognition pathway is effectively a VIP lane.
• 12:08
  Speaker 1: It's limited to those holding approvals from that specific list
• 12:11
  Speaker 1: of reference countries. It is so what happens to a
• 12:14
  Speaker 1: manufacturer who has a brilliant device, perhaps approved in several
• 12:18
  Speaker 1: non IMDRF countries, but lacks one of those specific golden tickets, Well.
• 12:23
  Speaker 2: They cannot use the fast track. They must take the
• 12:26
  Speaker 2: standard registration pathway, the scenic roup, the very scenic, paperwork
• 12:29
  Speaker 2: heavy route. This requires building a comprehensive, highly detailed technical
• 12:34
  Speaker 2: file from the ground up for the NMRA to review independently.
• 12:38
  Speaker 1: And this is where the required documentation scales aggressively alongside
• 12:41
  Speaker 1: the risk class. Oh.
• 12:42
  Speaker 2: Absolutely.
• 12:42
  Speaker 1: For example, if a manufacturer is submitting for dossier Class
• 12:46
  Speaker 1: B and above, the NMRA requires an ISO fourteen ninety
• 12:51
  Speaker 1: seven to one risk analysis.
• 12:52
  Speaker 2: Right and for those unfamiliar with that standard, and ISO
• 12:55
  Speaker 2: fourteen nine to seven one, risk analysis is not just the.
• 12:59
  Speaker 1: Simple checklist, it's pretty extensive.
• 13:01
  Speaker 2: It is a massive, living framework that proves the manufacturer
• 13:04
  Speaker 2: has analyzed every conceivable hazard associated with the device, from
• 13:09
  Speaker 2: electrical failures to user error, and it proves they have
• 13:13
  Speaker 2: implemented controls to mitigate those risks down to an acceptable level.
• 13:17
  Speaker 1: Additionally, they must provide an ISO thirteen four to eight
• 13:21
  Speaker 1: five Quality Management System Certificate.
• 13:23
  Speaker 2: Yes, and that standard proves organizational flawlessness. It demonstrates that
• 13:28
  Speaker 2: the manufacturer has a traceable, audited process for every step.
• 13:32
  Speaker 1: Of production, right, so you know what you're getting.
• 13:34
  Speaker 2: It assures the regulator that the device coming off the
• 13:36
  Speaker 2: assembly line today is identical in quality to the one
• 13:40
  Speaker 2: produced five years ago.
• 13:41
  Speaker 1: But the requirements keep climbing. Dossier CLASSY submissions require detailed
• 13:46
  Speaker 1: clinical evaluation reports and performance summaries. They do, and if
• 13:49
  Speaker 1: a manufacturer is bringing in a high risk dossier Class
• 13:52
  Speaker 1: D device. On the standard pathway, they need to hand
• 13:57
  Speaker 1: over the full clinical investigation data, every patient outcome, every
• 14:02
  Speaker 1: data point from their clinical trials.
• 14:04
  Speaker 2: Yeah. To contextualize the difference here, go ahead. Well, I mean, if.
• 14:08
  Speaker 1: The Global recognition pathway is like buying a fully inspected,
• 14:12
  Speaker 1: moving ready home, where you just need to check the
• 14:13
  Speaker 1: local zoning laws, the standard pathway means showing the NMRA
• 14:19
  Speaker 1: every single architectural blueprint, stress test and electrical schematic from scratch.
• 14:24
  Speaker 2: That is the perfect way to phrase it, and that
• 14:26
  Speaker 2: is why the timeline jumps from four months to potentially
• 14:28
  Speaker 2: eighteen months. The NMRA is undertaking the entire scientific evaluation internally.
• 14:35
  Speaker 1: So let's follow a manufacturer who successfully navigates one of
• 14:38
  Speaker 1: these pathways. They compile their technical file, or perhaps they
• 14:41
  Speaker 1: sail through the global recognition pathway. Okay, the paperwork is approved,
• 14:44
  Speaker 1: they might think they're ready to immediately capture the market.
• 14:47
  Speaker 2: And that is precisely where many international manufacturers trip right
• 14:50
  Speaker 2: at the finish line. Oh yeah, even with flawless science
• 14:54
  Speaker 2: and regulatory approval in hand, failing to respect Sri Lanka's
• 14:57
  Speaker 2: localized on the ground requirements will completely halt market access.
• 15:02
  Speaker 1: This brings us to the localized traps. The most common
• 15:05
  Speaker 1: deficiency the n MRA encounters involves labeling yes. On the surface,
• 15:11
  Speaker 1: adding a label seems like the easiest part of the process,
• 15:14
  Speaker 1: but the requirements are incredibly rigid.
• 15:16
  Speaker 2: They are for professional use devices equipment operated exclusively by surgeons, nurses,
• 15:23
  Speaker 2: or trained technicians, English labeling is generally accepted.
• 15:26
  Speaker 1: Okay, that's straightforward, But.
• 15:27
  Speaker 2: For patient self use devices the landscape changes entirely. The
• 15:31
  Speaker 2: NMRA may require the packaging and the instructions for use
• 15:34
  Speaker 2: to be fully translated into Sinhala, Tamil, or both.
• 15:38
  Speaker 1: Which is a requirement rooted in basic patient safety right.
• 15:41
  Speaker 1: If an individual is attempting to use a home diagnostic tool,
• 15:44
  Speaker 1: they must be able to comprehend the warnings and instructions
• 15:47
  Speaker 1: in their native language, otherwise the risk of improper use
• 15:50
  Speaker 1: guy rockets exactly.
• 15:51
  Speaker 2: Furthermore, it is not merely a matter of translation. A
• 15:54
  Speaker 2: manufacturer cannot simply ship a device with an existing European
• 15:57
  Speaker 2: or US label. The label must be customized to strip
• 16:01
  Speaker 2: out irrelevant foreign regulatory symbols that mean absolutely nothing in
• 16:05
  Speaker 2: Sri Lanka, while adding specific local nuances, oh like what
• 16:09
  Speaker 2: For instance, manufacturers must add the Sri Lanka registration number
• 16:13
  Speaker 2: to the label post registration. They need specific formatting for
• 16:17
  Speaker 2: the intended use warnings.
• 16:19
  Speaker 1: And batch numbers, so no generic labels.
• 16:22
  Speaker 2: Submitting an application with a generic, unadapted global label will
• 16:26
  Speaker 2: result in immediate pushback from the agency.
• 16:29
  Speaker 1: Good to know. But there is a trap even more
• 16:32
  Speaker 1: dangerous than improper labeling, and it involves corporate representation.
• 16:36
  Speaker 2: Ah yes, the local agent right.
• 16:38
  Speaker 1: If an international manufacturer does not have a formal legal
• 16:41
  Speaker 1: entity an actual registered corporate office inside Sri Lanka, they
• 16:46
  Speaker 1: are legally required to appoint and authorize local representative, often
• 16:50
  Speaker 1: referred to as a local agent.
• 16:51
  Speaker 2: This is a strict requirement. The local agent must hold
• 16:54
  Speaker 2: a valid business registration within the country and serve as
• 16:57
  Speaker 2: the official liaison between the foreign manufacturer and the NMRA.
• 17:01
  Speaker 1: So as a business operating globally. The instinct is often
• 17:05
  Speaker 1: to leverage existing infrastructure. If I'm a global manufacturer, I
• 17:09
  Speaker 1: already have a local distribution partner selling my bandages or
• 17:13
  Speaker 1: scanners in Colombo. Can I just name them as my
• 17:16
  Speaker 1: authorized representative to save time.
• 17:18
  Speaker 2: It is a very common assumption and it is arguably
• 17:21
  Speaker 2: the most dangerous operational mistake. A company can make by
• 17:25
  Speaker 2: that logistics distributors excel at moving boxes, managing supply chains,
• 17:30
  Speaker 2: and driving sales, but the authorized local representative bears comprehensive
• 17:34
  Speaker 2: legal accountability. They are not merely a mailing address for
• 17:38
  Speaker 2: the manufacturer.
• 17:39
  Speaker 1: What does that legal accountability actually look like? In practice?
• 17:42
  Speaker 1: Once the device is being sold.
• 17:44
  Speaker 2: It centers heavily on pharmacovigilance and post market surveillance okay.
• 17:48
  Speaker 2: Farm covigilance is the ongoing systematic monitoring of a medical
• 17:52
  Speaker 2: device's safety after it has hit the market. If an
• 17:55
  Speaker 2: adverse event occurs, say a batch of blood pressure monitors
• 17:58
  Speaker 2: starts delivering false readings due to the local humidity, or
• 18:02
  Speaker 2: a piece of surgical equipment malfunctions and harms a patient,
• 18:05
  Speaker 2: that authorized local representative is legally obligated to manage the incident,
• 18:10
  Speaker 2: reporting to the NMR WOW. They must facilitate product recalls,
• 18:15
  Speaker 2: manage ongoing label updates, and execute registration renewals, which are
• 18:19
  Speaker 2: required every three to five years.
• 18:21
  Speaker 1: So if a manufacturer appoints a logistics distributor who lacks
• 18:25
  Speaker 1: deep regulatory affairs competence, that distributor is not going to
• 18:29
  Speaker 1: know how to properly file an adverse event report, or
• 18:32
  Speaker 1: manage a complex regulatory renewal exactly.
• 18:36
  Speaker 2: And when they inevitably fail to meet those compliance standards,
• 18:40
  Speaker 2: the manufacturer's registration will either fail a compliance audit or
• 18:43
  Speaker 2: lapse entirely.
• 18:45
  Speaker 1: Ouch.
• 18:45
  Speaker 2: Yeah, And if a registration lapses in Sri Lanka, there
• 18:48
  Speaker 2: is no simple late fee to pay.
• 18:50
  Speaker 1: They don't just send you a bill.
• 18:51
  Speaker 2: Nope, the manufacturer loses their market access and must start
• 18:55
  Speaker 2: the entire eighteen month registration process over from scratch.
• 18:58
  Speaker 1: That's brutal.
• 19:00
  Speaker 2: The local agent requirement as an administrative afterthought, can literally
• 19:03
  Speaker 2: cost a company its entire footprint in the country. It
• 19:06
  Speaker 2: is vital to partner with actual regulatory affairs specialists on
• 19:10
  Speaker 2: the ground.
• 19:11
  Speaker 1: That makes total sense. When we pull all these pieces together,
• 19:15
  Speaker 1: Sri Lanka's twenty twenty six medical device landscape emerges as
• 19:19
  Speaker 1: a textbook example of modern regulatory evolution.
• 19:22
  Speaker 2: It really does.
• 19:23
  Speaker 1: We are seeing a system transition from historical informality into
• 19:28
  Speaker 1: a highly structured framework. They have established strict globally aligned
• 19:32
  Speaker 1: internal classifications and paired them with a deeply pragmatic recognition
• 19:37
  Speaker 1: of international approvals.
• 19:38
  Speaker 2: And you know, it perfectly balances the two most important
• 19:41
  Speaker 2: forces in healthcare regulation, which are safety and access. By
• 19:44
  Speaker 2: enforcing high standards for clinical evidence, risk management matrices like
• 19:48
  Speaker 2: ISO fourteen ninety seventy one, and localized labeling, they fiercely
• 19:52
  Speaker 2: protect the safety of their citizens right but by utilizing
• 19:55
  Speaker 2: the global recognition pathway, they do so without creating unnecessary
• 19:58
  Speaker 2: bureaucratic blockades. It eliminates redundant scientific trials, and.
• 20:03
  Speaker 1: It focuses energy where it matters most, ensuring a device
• 20:06
  Speaker 1: that was proven safe globally, it's implemented safely locally, exactly
• 20:11
  Speaker 1: so for you listening, whether you are directly managing a
• 20:14
  Speaker 1: corporate expansion into South Asia or simply analyzing how global
• 20:18
  Speaker 1: health systems function, this framework offers a clear blueprint.
• 20:22
  Speaker 2: It's a great model to study.
• 20:24
  Speaker 1: It demonstrates how emerging markets are overcoming limited institutional resources.
• 20:29
  Speaker 1: By trusting the rigorous science of major agencies. Through fast
• 20:32
  Speaker 1: track reliance pathways, companies can drastically accelerate their market access.
• 20:36
  Speaker 2: Which ultimately means getting life saving and life improving technologies
• 20:40
  Speaker 2: to patients months or even years faster than legacy systems
• 20:44
  Speaker 2: ever allowed.
• 20:44
  Speaker 1: It is a fascinating alignment of international standards, but it
• 20:48
  Speaker 1: leaves us with one final overarching question to ponder long
• 20:51
  Speaker 1: after this deep dive ends. What's that if smaller nations
• 20:54
  Speaker 1: are increasingly pooling their regulatory trust in major agencies like
• 20:58
  Speaker 1: the FDA and email through fastrack recognition pathways, where we
• 21:02
  Speaker 1: eventually see the creation of a universal global medical device passport,
• 21:06
  Speaker 1: rendering localized technical reviews entirely a thing of the past.